Home Mind & Brain Study Reveals Impact of Dopamine and Opioid Receptor Blockade on Reward Processing

Study Reveals Impact of Dopamine and Opioid Receptor Blockade on Reward Processing

Reading Time: 2 minutes

A recent study published in Human Brain Mapping has unveiled intriguing findings on the neural processing of social and nonsocial rewards, shedding light on the effects of dopamine and opioid receptor antagonism. The study by Claudia Massaccesi and colleagues aimed to increase our understanding of how these neurochemical systems affect the brain’s response to rewards.

Rewards are fundamental drivers of human behaviour, guiding motivation and decision-making. The study focuses on two critical components of reward processing: “wanting”, which refers to the motivation to pursue a reward, and “liking”, the pleasure associated with reward consumption. While extensive animal research has established the involvement of dopaminergic and opioidergic systems in these processes, human studies have been limited, especially concerning different types of rewards.

To address this gap, the researchers combined pharmacological interventions with functional neuroimaging techniques. The study employed a double-blind, placebo-controlled design involving 89 participants who received either the dopamine receptor antagonist amisulpride, the opioid receptor antagonist naltrexone, or a placebo. The effects of these drugs on the neural responses to anticipation and consumption of social (interpersonal touch) and nonsocial (food) rewards were analysed.

Participants underwent functional magnetic resonance imaging (fMRI) while engaging in tasks designed to elicit both anticipation and consumption of rewards. The rewards were carefully matched in terms of magnitude, primacy, and familiarity to ensure a fair comparison. Behavioural measures of wanting and liking were collected, alongside neural data.

The study showed that opioid antagonism significantly decreased activity in the medial orbitofrontal cortex (OFC) during the enjoyment of both social and nonsocial rewards compared to a placebo. This finding aligns with prior research highlighting the OFC’s role in encoding reward magnitude and hedonic value during consumption. However, dopamine antagonism did not show clear effects on brain activity during reward anticipation, challenging some previous assumptions about its role in human reward processing.

These findings have significant implications for our understanding of the neurobiology of reward. This lower activity in the medial OFC suggests that opioidergic signalling is important for the pleasure of reward consumption, whether the reward is social or not. This backs up the idea that opioids are a big part of the pleasure that comes from rewards. This is in line with studies on animals that have shown that stimulating the OFC with opioids makes hedonic reactions stronger.

On the other hand, the lack of significant effects from dopamine antagonism during reward anticipation raises questions about its precise role. While dopamine is traditionally linked to the motivation to pursue rewards, this study suggests that its influence might be more complex, possibly involving other neural pathways or interacting with different neurochemical systems.

The authors acknowledge the need for further research to fully elucidate the distinct roles of dopamine and opioids in reward processing. One area of interest is the potential involvement of other neurochemical systems, such as oxytocin and serotonin, which may differentially modulate social and nonsocial rewards. Additionally, investigating individual differences in baseline dopamine levels and their impact on reward processing could provide deeper insights.

The findings also highlight the importance of considering both anticipation and consumption phases in reward studies. Methodological variations, such as focusing solely on one phase or using unmatched reward stimuli, might contribute to the inconsistencies observed in previous research.

© Copyright 2014–2034 Psychreg Ltd